5:34 PM
 | 
Mar 18, 2009
 |  BC Extra  |  Top Story

FDA panel backs narrow Multaq label

FDA's Cardiovascular and Renal Drugs Advisory Committee voted 10-3 on Wednesday to recommend approval of Multaq dronedarone from sanofi-aventis (Euronext:SAN; NYSE:SNY) to treat patients with non-permanent atrial fibrillation (AF). However, the panel agreed that the label for the multichannel blocker with class I-IV antiarrhythmic properties...

Read the full 215 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >